Fractyl Projects $8 Million in Quarterly Operating Cash Spending by Q2 2027

Fractyl had $31.5 million in cash at quarter-end and expects additional capital will be needed to bring Revita to market.

Fractyl had $31.5 million in cash and cash equivalents on Sept. 30. The company expects that balance to fund operations through two planned milestones: a De Novo marketing application submission for Revita in late Q4 2026 and topline 12-month data from the REMAIN-1 Pivotal Cohort in Q1 2027.

Fractyl expects quarterly operating cash spending to decline to about $8 million by the end of Q2 2027.

Revita is an investigational endoscopic therapy intended to help people maintain weight loss after stopping GLP-1 treatment. In the study’s six-month results, participants receiving Revita retained about 80% of the weight they had lost on tirzepatide. The study met its six-month co-primary endpoint.

Fractyl plans to submit the De Novo application in late Q4 2026, followed by the REMAIN-1 Pivotal Cohort’s topline 12-month results in Q1 2027.